Biotech Models: Bypassing VCs to Deal Direct with Pharma

There has to be a better way to do biotech than lurching from one hard-fought VC round to the next, losing sight of product development for the sake of providing an exit for investors. That's the view of HS LifeSciences, which aims to create a more direct route from promising academic research to market, avoiding the management time, heartache and dilution associated with serial VC rounds. Put simply, the idea is to match innovative technologies or research projects with potential pharma partners very early on, bypassing VC funding and allowing maximum resource and attention to be focused on the product.

There has to be a better way to do biotech than lurching from one hard-fought VC round to the next, losing sight of product development for the sake of providing an exit for investors. That’s the view of (among others) biotech entrepreneurs Karsten Henco, PhD, and Edward Stuart, PhD, founders and Chairman and CEO respectively of Zurich-based consultancy HS LifeSciences. They’ve set up HS LifeSciences to help create a more direct route from promising academic research to market, avoiding the management time, heartache and dilution associated with serial VC rounds.

Put simply, the idea is to match innovative technologies or research projects with potential pharma partners very early on, bypassing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Roche, Following Sarepta, Pauses Elevidys Shipments In Certain Countries

 
• By 

Roche paused shipments of the Duchenne muscular dystrophy gene therapy in countries that reference US FDA approval of Elevidys after the agency asked Sarepta to pause US shipments; it remains available in Japan and Brazil.

More from Business

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By 

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

 
• By 

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.